2012年之前全球的HIV/AIDS市場發展預測

Shifting epidemiological demographics within the HIV marketplace, increasing resistance to current therapies and unmet needs within the patient population...only an intrinsic understanding of these issues can secure the commercial success of new drug developments. ‘The Global HIV/AIDS Market Outlook to 2012' is a new management report published by Business Insights that provides comprehensive coverage of the global HIV/AIDS market, incorporating a detailed epidemiological analysis of the prevalence of HIV/AIDS and key factors impacting prevalence in both the seven major pharmaceutical markets as well as emerging markets. This report analyses current leading brands of treatment within the HIV market, provides invaluable insights into market dynamics, profiles the leading pharmaceutical companies and details the key market trends influencing product sales. This new report will enable you to plan more effectively, evaluate key changes in the competitive landscape and identify potential growth areas in the global HIV/AIDS market.

Table of Contents

• Patient potential
• Global market analysis
• Pipeline analysis
• Competitive landscape

• Summary
• Introduction
• HIV/AIDS
• Overview
• Diagnosis, treatment and management
• Epidemiology
  • The global picture of HIV/AIDS
  • The seven major markets
• Forecast epidemiology
  • The seven major markets
  • Emerging markets

• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Market analysis by drug class
• Key events in the global HIV market
• Combivir loses blockbuster status
• FDA approves the first once-daily triple-combination pill for the treatment of
• HIV
• Fuzeon, the first-in-class fusion inhibitor enters the HIV market, offering an additional treatment option for patients requiring salvage therapy
• Approval of maraviroc
• Leading brand dynamics
• Leading brands of HIV treatments
• Market dynamics of leading nucleoside reverse transcriptase inhibitors Key NRTI brands
• Market dynamics of leading protease inhibitors Key protease inhibitor brands analysis
• Market dynamics of non nucleoside reverse transcriptase inhibitors Key NNRTI brands analysis
• HIV therapeutic market sales forecasts to 2011

• Summary
• Introduction
• Key trends in R&D
• The HIV therapeutic area pipeline
• Leading drugs in development
• Classification of pipeline products
  • Entry inhibitors
  • Maturation inhibitors
  • Integration inhibitors
  • New agents from existing classes
• Profiles of key pipeline products
• Phase II compounds
  • Bevirimat (PA-457)
• Phase III compounds
  • etravirine (TMC-125)
• Isentress (raltegravir)
• Recently marketed drugs/drugs in registration
• Maraviroc
• Prezista (darunavir)
• Atripla (efavirenz/ tenofovir/emtricitabine)
• Fuzeon (enfuviritide)
• Pipeline forecasts
• Factors affecting forecasts
• HIV pipeline forecasts

• Summary
• Introduction
• Company market shares
• GlaxoSmithKline
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Gilead
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
• Drivers of growth
• Resistors of growth
• Bristol-Myers Squibb
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Abbott
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Roche
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Boehringer Ingelheim
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Pfizer
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Merck
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Barr
• Overview
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Kohl Medical AG
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth

• Regional country groupings (UNAIDS)
• IMS data
• J5C HIV
• Index

• Figure 1.1: The HIV lifecycle
• Figure 1.2: Comparison of HIV treatment regimens
• Figure 1.3: Drivers of switching from first- to second-line ARV treatment regimens
• Figure 1.4: Estimated number of people living with HIV globally, 2005
• Figure 1.5: Unmet need for ARV therapy among adults in developing and transitional countries, 2005
• Figure 1.6 HIV patient segmentation across the seven major markets, 2005
• Figure 2.7: Global HIV/AIDS market share by geography, 2006
• Figure 2.8: Sales of types of HIV/AIDS brands, 2005-06
• Figure 2.9: Competitive dynamics of the global HIV/AIDS market by drug class, 2006
• Figure 2.10: Competitive dynamics of the leading treatments in the global HIV market, 2005-6
• Figure 2.11: Competitive dynamics of the leading NRTI brands in the global HIV market, 2005-6List of Tables
• Figure 2.12: Competitive dynamics of the leading protease inhibitor brands in the global HIV market, 2005-06
• Figure 2.13: Competitive dynamics of the leading NRTI brands in the global HIV market, 2005-6
• Figure 3.14: Prevailing R&D approaches, 2006
• Figure 3.15: The HIV pipeline by indication and stage of development, 2006
• Figure 3.16: Leading recently launched products and late-stage R&D compounds indicated for the treatment of HIV, 2006
• Figure 4.17: Competitive dynamics of the leading players in the global HIV market, 2006
• Figure 4.18: GSK' s HIV sales, 2006
• Figure 4.19: Gilead' s HIV sales, 2006
• Figure 4.20: BMS' HIV sales, 2006
• Figure 4.21: Abbott' s HIV sales, 2006
• Figure 4.22: Roche' s HIV sales, 2006
• Figure 4.23: Boehringer Ingelheim' s HIV sales, 2006
• Figure 4.24: Pfizer' s HIV sales, 2006
• Figure 4.25: Merck' s HIV sales, 2006
• Figure 4.26: Kohl' s HIV sales, 2006

• Table 1.1: Estimated prevalence of HIV/AIDS across the seven major markets, 2005
• Table 1.2: Forecast epidemiology of HIV/AIDS across the seven major markets, 2005-11
• Table 2.3: Breakdown of the global HIV market by drug class, 2002-06
• Table 2.4: Leading treatments in the global HIV market,
• Table 2.5: Leading NRTI products in the global HIV market, 2005 06
• Table 2.6: Leading protease inhibitor products in the global HIV market, 2005 06
• Table 2.7: Leading NNRTI products in the global HIV market, 2005 06
• Table 2.8: HIV treatment sales forecast, 2006-12
• Table 3.9: HIV pipeline forecasts, 2006-12
• Table 4.10: Leading players in the global HIV market, 2005-06
• Table 4.11: GSK' s HIV product portfolio, 2005-06
• Table 4.12: GSK' s HIV R&D product pipeline, 2006
• Table 4.13: Gilead' s HIV product portfolio, 2005-06
• Table 4.14: Gilead' s HIV R&D product pipeline, 2006
• Table 4.15: BMS' HIV product portfolio, 2005-06
• Table 4.16: BMS' HIV R&D product pipeline, 2006
• Table 4.17: Abbott' s HIV product portfolio, 2005-06
• Table 4.18: Roche' s HIV product portfolio, 2005-06
• Table 4.19: Roche' s HIV R&D product pipeline, 2006
• Table 4.20: Boehringer Ingelheim' s HIV product portfolio, 2005-06
• Table 4.21: Boehringer Ingelheim' s HIV R&D product pipeline, 2006
• Table 4.22: Pfizer' s HIV product portfolio, 2005-06
• Table 4.23: Pfizer' s HIV R&D product pipeline, 2006
• Table 4.24: Merck' s HIV product portfolio, 2005-06
• Table 4.25: Merck' s HIV R&D product pipeline, 2006
• Table 4.26: Barr' s HIV product portfolio, 2005-06
• Table 4.27: Kohl' s HIV product portfolio, 2005-06